Evidence map›Paper›PMID 39441401›Full record

ArticleJournal of gastroenterology2025

Possibility of determining high quantitative fecal occult blood on stool surface using hyperspectral imaging.

Hiroaki Ikematsu, Yohei Takara, Keiichiro Nishihara, Yuki Kano, Yuji Owaki, Ryuji Okamoto, Takahisa Fujiwara, Toshihiro Takamatsu, Masayuki Yamada, Yutaka Tomioka and 9 more

Abstract read
In one paragraph

Article in Journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hiroaki IkematsuDivision of Science and Technology for Endoscopy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan. hikemats@ims.u-tokyo.ac.jp.ORCID 0000-0001-9840-4588
Yohei TakaraEBA JAPAN Co., Ltd., Tokyo, Japan.
Keiichiro NishiharaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Yuki KanoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Yuji OwakiDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Ryuji OkamotoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Takahisa FujiwaraDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Toshihiro TakamatsuDivision of Science and Technology for Endoscopy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Masayuki YamadaEBA JAPAN Co., Ltd., Tokyo, Japan.
Yutaka TomiokaMedical Device Innovation Project Management Office, National Cancer Center Hospital East, Kashiwa, Japan.
Nobuyoshi TakeshitaDivision of Medical Device Innovation Support, National Cancer Center Hospital East, Kashiwa, Japan.
Atsushi InabaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Hironori SunakawaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Keiichiro NakajoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Tatsuro MuranoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Tomohiro KadotaDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Kensuke ShinmuraDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Yoshikatsu KogaDepartment of Strategic Programs, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
Tomonori YanoDivision of Science and Technology for Endoscopy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.

Funding

The National Cancer Center Research and Development Fund 2021-S-4
6 · The paper itself

Abstract

backgroundFecal immunochemical tests are commonly performed for colorectal cancer screening. Instant fecal occult blood measurement in toilet bowel movements would improve convenience. Hyperspectral imaging (HSI) enables the nondestructive evaluation of materials that are difficult to assess visually. This study aimed to determine whether HSI could be used to identify fecal occult blood on stool surfaces.

methodsThe study included 100 patients who underwent colonoscopy, divided into groups A and B (50 patients, each) for creating a discriminant algorithm and validating the accuracy of the algorithm, respectively. In group A, 100 areas were randomly selected from the stool surface, and the fecal occult blood quantitative values were measured and photographed using a hyperspectral camera (cutoff: > 400 ng/mL). A discriminant algorithm image was created to extract spectral feature differences obtained from HSI via machine learning. In group B, 250 random areas were evaluated and compared to fecal occult blood quantitative values, measuring sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV).

resultsGroups A and B comprised 28 and 26 patients with cancer, respectively. Cancer detection sensitivity at the 400 ng/mL cutoff was 67.9% and 42.3% in groups A and B, respectively. The discriminant algorithm image exhibited high accuracy in group A (sensitivity; 77.1%, specificity; 96.9%, accuracy; 90.0%, PPV; 93.1%, NPV; 88.7%). In group B, the sensitivity, specificity, accuracy, PPV, and NPV were 83.3, 92.9, 90.8, 76.3, and 95.3%, respectively.

conclusionHSI can effectively discriminate high quantitative fecal occult blood, highlighting its potential for improved colorectal cancer screening.

Indexed as

AlgorithmsColonoscopyColorectal NeoplasmsEarly Detection of CancerFecesHyperspectral ImagingOccult BloodAdultAgedAged, 80 and overFemaleHumansMachine LearningMaleMiddle AgedPredictive Value of TestsColorectal cancerColorectal cancer screeningFecal occult bloodHyperspectral imaging

Identifiers

PMID39441401
PMCPMC11717890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.